Live Breaking News & Updates on Statistics department of public health sciences

Stay informed with the latest breaking news from Statistics department of public health sciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Statistics department of public health sciences and stay connected to the pulse of your community

FDA Panel Votes That Phase 3 PFS Data for Sotorasib in KRAS G12C+ Advanced NSCLC Cannot Be Reliably Interpreted

In a 10-to-2 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the data for progression-free survival per blinded independent central review from the phase 3 CodeBreaK 200 trial evaluating sotorasib vs docetaxel for the treatment of patients with pretreated, locally advanced or metastatic KRAS G12C–mutated non–small cell lung cancer cannot be reliably interpreted.

Markr-conaway , Jorge-nieva , Ravia-madan , Jeevan-puthiamadathil , Division-of-translational-research , University-of-virginia-school-medicine , National-cancer-institute , Keck-school-of-medicine , Statistics-department-of-public-health-sciences , University-of-southern-california , Oncologic-drugs-advisory-committee , Drugs-advisory-committee